| 143.71 -0.09 (-0.06%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 178.36  |
1-year : | 186.1 |
| Resists | First : | 152.7 |
Second : | 159.33 |
| Pivot price | 148.47 |
|||
| Supports | First : | 141.97 |
Second : | 118.12 |
| MAs | MA(5) : | 144.75 |
MA(20) : | 149.16 |
| MA(100) : | 166.43 |
MA(250) : | 177.65 |
|
| MACD | MACD : | -2.4 |
Signal : | -2 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 10.7  |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 218.88 | Low : | 141.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALNY ] has closed above bottom band by 21.7%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 145.83 - 146.81 | 146.81 - 147.63 |
| Low: | 140.1 - 141.05 | 141.05 - 141.84 |
| Close: | 142.31 - 143.86 | 143.86 - 145.15 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 1-Year Low at $142.14 - MarketBeat
Thu, 25 Apr 2024
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research
Thu, 25 Apr 2024
Alnylam Pharmaceuticals (ALNY) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Thu, 18 Apr 2024
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results - Business Wire
Mon, 15 Apr 2024
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Simply Wall St
Tue, 19 Mar 2024
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 126 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 2,800 (K) |
| Shares Short P.Month | 3,040 (K) |
| EPS | -3.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.75 |
| Profit Margin | -24.1 % |
| Operating Margin | -26.5 % |
| Return on Assets (ttm) | -4.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 31.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.47 |
| EBITDA (p.s.) | -1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 104 (M) |
| Levered Free Cash Flow | 147 (M) |
| PE Ratio | -40.83 |
| PEG Ratio | 0.2 |
| Price to Book value | -82.13 |
| Price to Sales | 9.93 |
| Price to Cash Flow | 174.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|